Business Wire

TXONE-NETWORKS

25.4.2024 09:05:30 CEST | Business Wire | Press release

Share
New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover

TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment.

All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats.

SageOne essentially covers three main pillars:

  • CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the security information of various controls.
  • Integrated Lifecycle Protection: Centralized management simplifies cybersecurity governance and achieves collaborative defense. As an abstraction layer, SageOne streamlines the contextualization and consolidation of data across various products. It offers a tailored, task-oriented console designed specifically for executives, security personnel, and plant leaders.
  • CPS Threat Detection & Response: Properly handling known threats is absolutely crucial. Coping with unknown threats is equally important. SageOne compiles all security insights from multiple solutions and scouts for potential risks in order to enable early caution and response when needed.

To achieve this goal, the platform includes the following key components:

  • Threat intelligence means collecting, analysing and applying knowledge about potential and existing threats against a CPS. The TXOne Threat Research department carries out a large number of investigations into vulnerabilities in Industrial Control Systems (ICS) devices and protocols. It analyses malware and ransomware in connection with Operational Technology (OT) threats. This information can also come from a variety of other sources: Publicly available data, industry reports and private sector information.
  • Behaviour-based AI analytics engines use artificial intelligence to monitor and analyse the behaviour of users, devices and systems within a CPS. This advanced analytics engine learns the normal behavioural patterns of these entities and can detect unusual activity or anomalies that could indicate a security threat.
  • The Compliance Framework provides a structured approach to compliance with relevant safety standards and regulations. It includes policies, procedures and controls to ensure that every system complies with legal requirements, industry standards and security best practices.
  • The Data Visualiser is a tool that transforms complex safety data and metrics into an easy-to-understand visual form. Using diagrams, graphs and network maps, security professionals can recognise patterns and trends as well as anomalies more quickly.
  • The Ecosystem Integrator helps to seamlessly integrate different tools and technologies. This includes standardising data formats, promoting the interoperability of different systems and creating a coherent security architecture that covers the entire ecosystem. This enables security forces to obtain a standardised overview of the security situation, automate processes and respond more effectively to threats.

SageOne focuses on the analysis of unexpected behaviour and unknown threats. Suspicious events can be identified by comparing endpoint and network telemetry within the OT-native XDR (Extended Detection and Response) engine. The platform thus combines advanced technologies with a user-friendly interface to ensure the protection of critical infrastructures. To achieve reliable CPS attack surface management, SageOne also offers Asset Centric Visibility to provide full visibility of any device on the network. In addition, the analysis of the attack surface is prioritised and recommendations are made.

To enable a rapid response to threats, SageOne can issue early warnings of suspicious behaviour in the network as part of CPS Threat Detection & Response Orchestration using cross-telemetry analysis.

In addition, Integrated Lifecycle Protection protects devices and systems over their entire service life. The centralised management of the security solutions and the unified defence under one roof contribute to this, resulting in high cost efficiency. With SageOne, TXOne Networks emphasises its commitment to the security and reliability of CPS and continuously drives the development of OT security.

Visit TXOne Networks at the Hannover Messe from 22nd to 26th April 2024 at booth B06 in hall 16.

Follow TXOne Networks on the blog, Twitter and LinkedIn.

About TXOne Networks

TXOne Networks provides OT security products that ensure the reliability and security of industrial control systems and operational technology environments through the OT Zero Trust methodology. TXOne Networks works with both leading industrial manufacturers and critical infrastructure operators to develop practical and business-friendly approaches to OT defence. TXOne Networks offers both network and endpoint-based products to secure OT networks and mission-critical devices in real-time and with high security depth. www.txone.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240420367607/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye